Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) - USD ($)	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Non-controlling Interest	Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending balance (in shares)			153,950,895
Beginning balance (in shares) at Dec. 31, 2021			153,950,895
Beginning balance at Dec. 31, 2021	$ 670,881,000	$ (75,264,000)	$ 16,000	$ 1,691,206,000	$ (87,946,000)	$ (1,009,293,000)	$ 12,682,000	$ (11,220,000)	$ 172,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock/At-the-market offering, net of offering costs (in shares)			27,443,580
Issuance of common stock/At-the-Market offering, net of offering costs	203,796,000		$ 2,000	203,794,000
Exercise of common stock warrants (in shares)			540,541
Exercise of warrants	10,249,000			10,249,000
Exercise of stock options (in shares)			349,847
Exercise of stock options	443,000			443,000
Delivery of common stock underlying restricted stock units (in shares)			392,326
Stock-based compensation	19,449,000			19,449,000
Foreign currency translation adjustment	(2,215,000)								(2,215,000)
Net loss attributable to non-controlling interest	(93,000)							(93,000)
Net loss attributable to common shareholders	(140,724,000)					(140,724,000)
Ending balance at Mar. 31, 2022	$ 686,522,000		$ 18,000	1,837,195,000		(1,137,335,000)		(11,313,000)	(2,043,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending balance (in shares)			182,677,189
Ending balance (in shares)	209,684,548		209,684,548
Beginning balance (in shares) at Dec. 31, 2022	209,684,548		209,684,548
Beginning balance at Dec. 31, 2022	$ 401,682,000		$ 21,000	1,972,006,000		(1,558,088,000)		(11,662,000)	(595,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock/At-the-market offering, net of offering costs (in shares)			71,444,729
Issuance of common stock/At-the-Market offering, net of offering costs	$ 106,057,000		$ 7,000	106,050,000
Exercise of stock options (in shares)	28,663		28,663
Exercise of stock options	$ 46,000			46,000
Cancellation of escrow shares in connection with Edisn acquisition (in shares)			(12,595)
Cancellation of escrow shares in connection with Edisn acquisition	(344,000)			(344,000)
Delivery of common stock underlying restricted stock units (in shares)			454,462
Stock-based compensation	11,738,000			11,738,000
Molotov non-controlling interest	(499,000)			(864,000)				374,000	(9,000)
Foreign currency translation adjustment	2,756,000								2,756,000
Net loss attributable to non-controlling interest	(11,000)							(11,000)
Net loss attributable to common shareholders	(83,613,000)					(83,613,000)
Ending balance at Mar. 31, 2023	$ 437,812,000		$ 28,000	$ 2,088,632,000		$ (1,641,701,000)		$ (11,299,000)	$ 2,152,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending balance (in shares)	281,599,807		281,599,807